TORONTO, Oct. 3 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced that it has appointed Zafeer Ahmad, Ph.D, to the position of Vice President, Manufacturing Operations, and that it has accepted the resignation of Kerry M. Barnhart, Ph.D, as President and Chief Scientific Officer effective November 1, 2007. Chief Executive Officer Alan M. Ezrin, Ph.D. will assume the additional role of President.
"Dr. Ahmad brings a wealth of knowledge in late-stage drug development. As we prepare to submit our proposed multi-center Phase III trial protocol and manufacturing data for Neuradiab to the FDA, Dr. Ahmad's experience in working with contract research and contract manufacturing organizations will be indispensable to Bradmer. Zafeer will also be a strong addition to our team as we complete the validation and transfer of drug production from Duke University to a commercial manufacturer," said Dr. Ezrin, Chief Executive Officer of Bradmer. "Dr. Barnhart made a significant contribution to Bradmer at an early stage and we wish him our best as he pursues other opportunities. His decision to leave at this stage, after we've recruited a team with broad experience in preparation for initiating the Phase III trial, will allow us to make a seamless transition in the roles and responsibilities of the existing management team."
Dr. Ahmad most recently held the position of Vice President, Process
Development and Manufacturing at NeoPharm, Inc. Prior to his work with
NeoPharm, Dr. Ahmad held senior positions at GlaxoSmithKline plc and
Hoffmann-La Roche Inc. He has more than 19 years of industry experience in
drug development, aseptic manufacturing operations, facility design and
validation, batch record and SOP preparation, outsourcing, tech transfer,
process validation and regulatory submission of drugs.
|SOURCE Bradmer Pharmaceuticals Inc.|
Copyright©2007 PR Newswire.
All rights reserved